Early Cytogenetic or Molecular Landmark Response to Ponatinib Treatment Predicts Outcomes in Heavily Pretreated Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in PACE: 5-Year Data
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA（2023）
关键词
CML, chronic myeloid leukemia, mutation, protein kinase inhibitor, antineoplastic, ponatinib
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要